Skip to main content
Home
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
      • Specialties
        • Vaccines & Infectious Diseases
        • Ophthalmology
        • Clinical Neuroscience
        • Rare Disease
        • Cell & Gene Therapy
        • Government
      • Additional Specialties
        • Hematology
        • Oncology
        • Maternal & Child Health
        • Medical Devices
      • Clinical Services
        • Biostatistics
        • Clinical Data Management
        • Clinical Research Services
        • Clinical Trial Management
        • Global Regulatory Affairs
        • Pharmacovigilance & Medical Monitoring
    • Veridix - Tech & AI
      • eClinical Platform
        • EDC
        • Decentralized Clinical Trials
        • Health Navigator
        • RTSM
        • eCOA / ePRO
      • AI Agents
        • Biostats and Analysis Agent
        • Data Management Agent
        • Document Authoring
      • GlobalTrace
      • Analytics & Reporting
        • Clinical Pipelines
        • VERA
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us

Breadcrumb

  1. Emmes Group

Vaccination success rate and reaction profile with diluted and undiluted smallpox vaccine

Go back to Resources

Vaccination success rate and reaction profile with diluted and undiluted smallpox vaccine

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Uveitis therapy: a phase II study using subcutaneously administered daclizumab

Go back to Resources

Uveitis therapy: a phase II study using subcutaneously administered daclizumab

Authors:

Location:

Go back to Resources

Untitled

Go back to Resources

Untitled

Authors:

Location:

Go back to Resources

The relationship of Tacrolimus blood levels to efficacy and adverse events in kidney transplant patients treated with mycophenolate mofetil (MMF) or Sirolimus

Go back to Resources

The relationship of Tacrolimus blood levels to efficacy and adverse events in kidney transplant patients treated with mycophenolate mofetil (MMF) or Sirolimus

Authors:

Location:

Go back to Resources

The Effect of Ruboxistaurin (RBX), a PKC b Inhibitor, on Visual Acuity (VA) Loss Due to Diabetic Macular Edema (DME)

Go back to Resources

The Effect of Ruboxistaurin (RBX), a PKC b Inhibitor, on Visual Acuity (VA) Loss Due to Diabetic Macular Edema (DME)

Authors:

Location:

Go back to Resources

The Advanced Glaucoma Intervention Study (AGIS): 14. Distinguishing Progression of Glaucoma from Visual Field Fluctuations

Go back to Resources

The Advanced Glaucoma Intervention Study (AGIS): 14. Distinguishing Progression of Glaucoma from Visual Field Fluctuations

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Abstract:

Go back to Resources

The Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race. Ten-year results

Go back to Resources

The Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race. Ten-year results

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Tacrolimus Ointment is Effective for Facial and Intertriginous Psoriasis

Go back to Resources

Tacrolimus Ointment is Effective for Facial and Intertriginous Psoriasis

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Tacrolimus ointment for the treatment of eyelid dermatitis

Go back to Resources

Tacrolimus ointment for the treatment of eyelid dermatitis

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Substitution of a telephone battery for an in-clinic assessment of cognitive function: correlation analysis from the AREDS Cognitive Function Ancillary Study

Go back to Resources

Substitution of a telephone battery for an in-clinic assessment of cognitive function: correlation analysis from the AREDS Cognitive Function Ancillary Study

Authors:

Location:

Go back to Resources

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 141
  • Page 142
  • Page 143
  • Page 144
  • Current page 145
  • Page 146
  • Page 147
  • Page 148
  • Page 149
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to
Emmes Group

Delivering Global Health
Impact Through People,
Science and Technology

Main navigation
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
    • Veridix - Tech & AI
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us

Copyright ©, The Emmes Company, LLC

Footer
  • Cookie Policy
  • External Privacy Notice
  • FCOI
  • Emmes EU-U.S. Data Privacy Framework
  • Purchasing Terms and Conditions